Evidence map›Paper›PMID 37368310›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Osteogenic Potential of Nano-Hydroxyapatite and Strontium-Substituted Nano-Hydroxyapatite.

Georgia-Ioanna Kontogianni, Catarina Coelho, Rémy Gauthier, Sonia Fiorilli, Paulo Quadros, Chiara Vitale-Brovarone, Maria Chatzinikolaidou

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Georgia-Ioanna KontogianniDepartment of Materials Science and Technology, University of Crete, 70013 Heraklion, Greece.
Catarina CoelhoFLUIDINOVA S.A., 4475-188 Maia, Portugal.ORCID 0000-0002-7049-8030
Rémy GauthierDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Turin, Italy.ORCID 0000-0002-0479-4165
Sonia FiorilliDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Turin, Italy.
Paulo QuadrosFLUIDINOVA S.A., 4475-188 Maia, Portugal.ORCID 0000-0002-7207-1110
Chiara Vitale-BrovaroneDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Turin, Italy.
Maria ChatzinikolaidouDepartment of Materials Science and Technology, University of Crete, 70013 Heraklion, Greece.ORCID 0000-0002-2749-2506

Funding

European Union's Horizon 2020 814410
6 · The paper itself

Abstract

Nanohydroxyapatite (nanoHA) is the major mineral component of bone. It is highly biocompatible, osteoconductive, and forms strong bonds with native bone, making it an excellent material for bone regeneration. However, enhanced mechanical properties and biological activity for nanoHA can be achieved through enrichment with strontium ions. Here, nanoHA and nanoHA with a substitution degree of 50 and 100% of calcium with strontium ions (Sr-nanoHA_50 and Sr-nanoHA_100, respectively) were produced via wet chemical precipitation using calcium, strontium, and phosphorous salts as starting materials. The materials were evaluated for their cytotoxicity and osteogenic potential in direct contact with MC3T3-E1 pre-osteoblastic cells. All three nanoHA-based materials were cytocompatible, featured needle-shaped nanocrystals, and had enhanced osteogenic activity in vitro. The Sr-nanoHA_100 indicated a significant increase in the alkaline phosphatase activity at day 14 compared to the control. All three compositions revealed significantly higher calcium and collagen production up to 21 days in culture compared to the control. Gene expression analysis exhibited, for all three nanoHA compositions, a significant upregulation of osteonectin and osteocalcin on day 14 and of osteopontin on day 7 compared to the control. The highest osteocalcin levels were found for both Sr-substituted compounds on day 14. These results demonstrate the great osteoinductive potential of the produced compounds, which can be exploited to treat bone disease.

Indexed as

bone regenerationcytotoxicityosteogenic differentiationosteoinductionpre-osteoblastsRT-qPCR

Identifiers

PMID37368310
PMCPMC10304422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.